A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

• Status: RECRUITING
• Trial end date: 2032-06-22

Summary

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

• Phase: PHASE3

Details

• Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• Collaborator: Celgene Corporation
• Treatments: carfilzomib; Cyclophosphamide; daratumumab; Dexamethasone; fludarabine; pomalidomide